Is Sandu Pharma. overvalued or undervalued?

As of 12 November 2025, Sandu Pharma's valuation grade has moved from attractive to fair, indicating a reassessment of its market position. The company is currently fairly valued, with a PE ratio of 27.25, an EV to EBITDA ratio of 14.67, and a PEG ratio of 4.84. These figures suggest that while Sandu Pharma is not excessively priced, it does not present a compelling buying opportunity at this time.
In comparison to its peers, Sandu Pharma's valuation metrics are significantly lower than those of Elitecon International, which is considered very expensive with a PE ratio of 329.04, and MMTC, which has a PE ratio of 141.11. On the other hand, Optiemus Infra is also rated fair, with a PE of 78.25, highlighting that Sandu Pharma is positioned reasonably within its competitive landscape. Notably, Sandu Pharma's recent stock performance has lagged behind the Sensex, with a year-to-date return of -23.16% compared to the Sensex's 8.10%, reinforcing the notion that the stock is currently fairly valued.